{4-(4-Chloro-phenyl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-butylsulfanyl}-acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: {4-(4-Chloro-phenyl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-butylsulfanyl}-acetic acid
• 英文别名: 2-[4-(4-chlorophenyl)-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic acid
• 化学式: C₂₈H₂₆ClNO₃S
• 分子量: 492.0
• InChiKey: QEJSGEVFYKLAOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS<br/>[FR] bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES SYMETRIQUES INHIBANT LA BIOSYNTHESE DE LEUKOTRIENE
  申请人：ABBOTT LABORATORIES

  公开号：WO1997012867A1

  公开（公告）日：1997-04-10

  (EN) Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.(FR) L'invention porte sur des composés représentés par la formule (I), où W est identique à chaque occurrence, et est choisi parmi quinolyle facultativement substitué, benzothiazolyle facultativement substitué, benzoxazolyle facultativement substitué, benzimidazolyle facultativement subtitué, quinoxalyle facultativement substitué, pyridyle facultativement substitué, pyrimidyle facultativement substitué, et thiazolyle facultativement substitué; R1 et R2 sont choisis chacun séparément parmi hydrogène, alkyle, haloalkyle, alcoxy, halogène; R3 est une liaison de valence ou est choisi parmi hydrogène et alkyl; et Z est choisi parmi (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM où A est choisi parmi alkylène et cycloalkylène, et M est choisi parmi (A) un groupe métaboliquement clivable et pharmaceutiquement acceptable, (b) -OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, et (f) glycinyle. Ces composés inhibent la biosynthèse de leukotriène, et sont utilisés dans le traitement d'allergies et d'inflammations. L'invention porte également sur des compositions inhibant la biosynthèse de leukotriène et sur un procédé d'inhibition de la biosynthèse de leukotriène.

  化合物的化学式为（I），其中W在每次出现时相同，并从可选择的取代的喹啉基，可选择的取代的苯并噻唑基，可选择的取代的苯并噁唑基，可选择的取代的苯并咪唑基，可选择的取代的喹喔啉基，可选择的取代的吡啶基，可选择的取代的嘧啶基和可选择的取代的噻唑基中选择; R1和R2分别选择自氢，烷基，卤代烷基，烷氧基，卤素; R3是一个价键或选择自氢和烷基; X是一个价键或选择自烷基，烯基和炔基; Z选择自（a）COM，（b）CH = N-O-A-COM，（c）CH2-O-N = A-COM，其中A选择自烷基和环烷基，M选择自（a）药理学上可接受的代谢可裂解基团，（b）-OR6，（c）-NR7R8，（d）-NR6SO2R9，（e）-NH-Tetrazolyl和（f）甘氨酰基。这些化合物抑制白三烯生物合成，可用于治疗过敏和炎症性疾病状态。还公开了抑制白三烯生物合成的组合物和一种抑制白三烯生物合成的方法。
• Quinoline ether alkanoic acid
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0349062A1

  公开（公告）日：1990-01-03

  Compounds having the formula: are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

  具有以下式子的化合物 是白三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗腹泻、高血压、心绞痛、血小板聚集、脑痉挛、早产、自然流产、痛经和偏头痛。
• IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
  申请人：Abbott Laboratories

  公开号：EP0772594A1

  公开（公告）日：1997-05-14
• SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
  申请人：Abbott Laboratories

  公开号：EP0862557A1

  公开（公告）日：1998-09-09
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.